157 related articles for article (PubMed ID: 14727246)
21. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.
Büntzel J; Küttner K; Fröhlich D; Glatzel M
Ann Oncol; 1998 May; 9(5):505-9. PubMed ID: 9653491
[TBL] [Abstract][Full Text] [Related]
22. [Comments on five clinical trials concerning radiotherapy-induced mucositis in patients with head and neck neoplasms].
Noël G; Mazeron JJ
Cancer Radiother; 2001 Apr; 5(2):202-4. PubMed ID: 11355589
[No Abstract] [Full Text] [Related]
23. Chemoradiotherapy for head and neck cancer: 'local' side effects are actually systemic.
J Support Oncol; 2006 Feb; 4(2):88. PubMed ID: 16499131
[No Abstract] [Full Text] [Related]
24. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
26. A randomized phase II trial of amifostine for head and neck irradiation in lymphoma.
Ng AK; Hickey G; Li S; Neuberg D; Mauch PM
Semin Oncol; 2004 Dec; 31(6 Suppl 18):20-4. PubMed ID: 15726518
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
[TBL] [Abstract][Full Text] [Related]
28. [Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
Büntzel J; Glatzel M; Schuth J; Weinaug R; Küttner K; Fröhlich D
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():37-40. PubMed ID: 10584140
[TBL] [Abstract][Full Text] [Related]
29. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
Antonadou D; Petridis A; Synodinou M; Throuvalas N; Bolanos N; Veslemes M; Sagriotis A
Semin Oncol; 2003 Dec; 30(6 Suppl 18):2-9. PubMed ID: 14727235
[TBL] [Abstract][Full Text] [Related]
30. Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma.
Carter DL; Asmar L; Barrera D; Caracandas J; Dakhil JS; McCracken D; O'Rourke MA; Rosenberg RK; Boehm KA; Ilegbodu D; Reid RL
Invest New Drugs; 2008 Oct; 26(5):473-81. PubMed ID: 18473121
[TBL] [Abstract][Full Text] [Related]
31. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
[TBL] [Abstract][Full Text] [Related]
32. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium.
Hainsworth JD; Spigel DR; Greco FA; Shipley DL; Peyton J; Rubin M; Stipanov M; Meluch A
Cancer J; 2011; 17(5):267-72. PubMed ID: 21952273
[TBL] [Abstract][Full Text] [Related]
33. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Meluch AA; McClurkan S; Gray JR; Stroup SL; Burris HA; Yardley DA; Bradof JE; Yost K; Ellis JK; Greco FA
Cancer J; 2002; 8(4):311-21. PubMed ID: 12184409
[TBL] [Abstract][Full Text] [Related]
34. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
[TBL] [Abstract][Full Text] [Related]
35. Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials.
Gu J; Zhu S; Li X; Wu H; Li Y; Hua F
PLoS One; 2014; 9(5):e95968. PubMed ID: 24788761
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Anné PR
Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
[TBL] [Abstract][Full Text] [Related]
37. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
Mehta V
Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
[TBL] [Abstract][Full Text] [Related]
38. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Altmann S; Hoffmanns H
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
[TBL] [Abstract][Full Text] [Related]
39. Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes.
Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Ferreli L; Camboni P; Lusso MR; Mocci M; Madeddu C; Mura L; Mudu MC; Proto E; Tore G; Mura M; Macciò A; Ferreli A; Amichetti M
Oncol Rep; 2003; 10(3):759-66. PubMed ID: 12684655
[TBL] [Abstract][Full Text] [Related]
40. Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.
Werner-Wasik M; Langer C; Movsas B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):47-51. PubMed ID: 15726523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]